Download Biotechnology - Nexia Australia

Biotechnology
Industry at a glance
The Biotechnology industry is considered
to be in a growth phase of its economic
life cycle. There are numerous new
companies entering the industry each
year. Despite slowing down since 2007-08,
due to the uncertain economic climate
spurred on by the US subprime mortgage
crisis and subsequent global recession,
industry value added (the measure of the
industry’s contribution to the economy)
is expected to grow by 3.0% per annum
over the 10 years through 2018-19, which
is above the expected GDP growth of 2.5%
over the same period.
Over the next five years, most new
entrants are expected to be small firms
that concentrate on a single product
line. In the medium to long term, as
the industry matures, there will be a
downward pressure on market share
concentration as a wider range of firms
brings products to market resulting in a
broader distribution of sales revenue.
Critical success factors
The industry is exposed to various
critical success factors, which will impact
performance in the coming years. These
include, but are not limited to:
■■
Access to a highly skilled workforce
that can adapt to the ever changing
demands
■■
Access to funding, equity and R & D
concessions
■■
Ability to develop products and
solutions to niche markets
■■
Collaboration amongst industry
participants to advance
developments and technologies
■■
Commercialization of activities
■■
Ability to quickly adopt new
technologies
■■
Responsible corporate governance
and risk management practices
Key industry drivers
The industry outlook for the next five years
has identified a number of critical drivers
requiring focus and attention. These
include:
How we can help
Our experienced teams work closely
with you to establish a plan that suits the
specific needs of the organisation. We pride
ourselves on our ability to understand
the issues and drivers associated with
the Biotechnology industry, offer practical
solutions and support the team to make
strategic decisions.
We add value through:
■■
Accounting, Tax & Corporate
Compliance
■■
Taxation Advisory
■■
Audit & Risk Management
■■
Corporate Advisory & Transaction
Support
■■
Superannuation Compliance
■■
Finance Structuring & Procurement
■■
Business Consulting & Development
■■
Business Succession
Structures and incentives to
remunerate and retain talent need to
be creative
■■
Estate Planning & Wills Administration
■■
Litigation Support & Forensic
Accounting
■■
Total spending on health concerns
will influence the market
■■
International Desk
■■
Family Office
■■
A strong share market will assist
biotechnology companies to raise
capital and generate a healthy
appetite for technology
■■
Financial Services
■■
Remuneration Structures & Strategy
■■
Grant Strategy Development
■■
R&D Compliance and Strategies
■■
Capital & Debt Raising Assistance
■■
Risk Management
■■
Corporate Governance
■■
Cash Flow Modelling & Management
■■
■■
■■
The expectation of increased
commercialized activities, changes
to R&D tax systems and the shift
in industry focus within Australia
means that private research
and development expenditure is
expected to increase to assist in the
commercialization of activities
Expected increased
commercialization of existing
research will help drive interest and
success
Independent member of Nexia International
Adelaide | Brisbane | Canberra | Melbourne | Perth | Sydney | Christchurch
www.nexia.com.au